OBJECTIVE: To probe into the clinical efficacy of silibinin combined with entecavir in treatment of liver cirrhosis of hepatitis B .METHODS:72 patients with liver cirrhosis of hepatitis B admitted into Ningxia People 's Hospital from Jan.2016 to Jan.2017 were selected and divided into observation group and control group via random number table , with 36 cases in each .The control group was treated with entecavir , while the observation group was given silibinin based on the control group .The liver function indicators , liver fibrosis indicators and incidence of adverse drug reactions of two groups were observed .RESULTS: After treatment , levels of alanine aminotransferase , prothrombin time , serum total bilirubin and albumin of two groups were better than those of before treatment , and the observation group was better than the control group , with statistical significance ( P <0.05 ) .After treatment, the hyaluronic acid , type Ⅳprocollagen and type Ⅲprocollagen levels were better than those of before treatment , and the observation group was better than the control group , with statistical significance(P<0.05).The incidence of adverse drug reactions of observation group was 11.12％( 4/36 ) , significantly lower than that of control group [ 30.58％( 11/36 ) ] , with statistical significance ( P<0.05 ) .CONCLUSIONS:The efficacy of silibinin combined with entecavir in treatment of liver cirrhosis of hepatitis B is remarkable , which can effectively improve levels of liver function indicators and liver fibrosis indicators with fewer adverse drug reactions .%目的:探讨水飞蓟宾联合恩替卡韦治疗乙型病毒性肝炎肝硬化的临床疗效.方法:选取2016年1月—2017年1月宁夏回族自治区人民医院收治的乙型病毒性肝炎肝硬化患者72例作为研究对象,以随机数字表法分为观察组和对照组,每组36例.对照组患者给予恩替卡韦,观察组患者在对照组的基础上加用水飞蓟宾.观察两组患者的肝功能、肝纤维化指标水平和不良反应发生情况.结果:治疗后,两组患者丙氨酸氨基转移酶、凝血酶原时间、血清总胆红素和白蛋白水平明显优于治疗前,且观察组患者明显优于对照组,差异均有统计学意义(P<0.05);两组患者透明质酸、Ⅳ型胶原和Ⅲ型前胶原水平明显优于治疗前,且观察组患者明显优于对照组,差异均有统计学意义(P<0.05);观察组患者不良反应发生率为11.12％(4/36),明显低于对照组的30.58％(11/36),差异有统计学意义(P<0.05).结论:水飞蓟宾联合恩替卡韦治疗乙型病毒性肝炎肝硬化的疗效显著,可有效改善患者肝功能、肝纤维化指标水平,且不良反应少.
展开▼
